



Correction to: Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)

Daniel P. Judge^{1,2} · Arnt V. Kristen³ · Martha Grogan⁴ · Mathew S. Maurer⁵ · Rodney H. Falk⁶ · Mazen Hanna⁷ · Julian Gillmore⁸ · Pushkal Garg⁹ · Akshay K. Vaishnav⁹ · Jamie Harrop⁹ · Christine Powell⁹ · Verena Karsten⁹ · Xiaoping Zhang⁹ · Marianne T. Sweetser⁹ · John Vest⁹ · Philip N. Hawkins⁸

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Correction to: Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)

Article information

The original article contained incorrect terminology for one of the cardiac measures; throughout the manuscript and supplementary information ‘*intraventricular septum wall thickness*’ should have been given as ‘*interventricular septum wall thickness*’. Corrections should also be noted for Tables 1 and 4: in the Table 1 legend ‘*Low risk – Neither above at baseline*’ should read ‘*Low risk – Neither above threshold at baseline*’; in Table 4, the rows ‘*Mild: eGFR > 60 to < 90 ml/min/1.73 m²*’ and ‘*Moderate: eGFR > 30 to < 60 ml/min/1.73 m²*’ should

read ‘*Mild: eGFR ≥ 60 to < 90 ml/min/1.73 m²*’ and ‘*Moderate: eGFR ≥ 30 to < 60 ml/min/1.73 m²*’, respectively. The original article also contained a mistake in the text of the Pharmacokinetics sub-section of Results; ‘*There were no apparent differences in revusiran C_{max} between patients with mild (eGFR: 30 and < 60 ml/min/1.73 m²) or moderate (eGFR: 60 to < 90 ml/min/1.73 m²) renal impairment when compared with patients with normal (eGFR: ≥ 90 ml/min/1.73 m²) renal function at Weeks 0, 26, and 52 (p > 0.20) (Supplementary Fig. 6)*’ should read ‘*There were no apparent differences in revusiran C_{max} between patients with mild (eGFR: ≥ 60 to < 90 ml/min/1.73 m²) or moderate (eGFR: ≥ 30 and < 60 ml/min/1.73 m²) renal impairment when compared with patients with normal (eGFR: ≥ 90 ml/min/1.73 m²) renal function at Weeks 0, 26, and 52 (p > 0.20) (Supplementary Fig. 6)*’.

The online version of the original article can be found at <https://doi.org/10.1007/s10557-019-06919-4>

✉ Philip N. Hawkins
p.hawkins@ucl.ac.uk

- ¹ Johns Hopkins Hospital, Baltimore, MD, USA
- ² Present address: Medical University of South Carolina, Charleston, SC, USA
- ³ Department of Cardiology, University of Heidelberg, Heidelberg, Germany
- ⁴ Mayo Clinic, Rochester, MN, USA
- ⁵ Columbia University Medical Center, New York, NY, USA
- ⁶ Brigham and Women’s Hospital, Boston, MA, USA
- ⁷ Cleveland Clinic, Cleveland, OH, USA
- ⁸ National Amyloidosis Centre, Division of Medicine, UCL Medical School, Royal Free Hospital, Rowland Hill Street, NW3 2PF, London, UK
- ⁹ Anylam Pharmaceuticals, Cambridge, MA, USA

Cardiovasc Drugs Ther. 2020 Feb 15

Published online 2020 Feb 15. doi: <https://doi.org/10.1007/s10557-019-06919-4>

PMID: 32062791

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. This corrects the article “Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)” in *Cardiovasc Drugs Ther*, published Online First on 15th February 2020.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.